A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
Authors
Keywords
Fostamatinib, R406, R935788, Solid tumors, Angiogenesis
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 71, Issue 4, Pages 981-990
Publisher
Springer Nature
Online
2013-02-12
DOI
10.1007/s00280-013-2091-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
- (2011) Shivaani Kummar et al. EUROPEAN JOURNAL OF CANCER
- Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis
- (2011) Muhammad Baluom et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Involvement of the Syk–mTOR pathway in follicular lymphoma cell invasion and angiogenesis
- (2011) S Fruchon et al. LEUKEMIA
- Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients
- (2010) M. Ronzoni et al. ANNALS OF ONCOLOGY
- Metabolism of Fostamatinib, the Oral Methylene Phosphate Prodrug of the Spleen Tyrosine Kinase Inhibitor R406 in Humans: Contribution of Hepatic and Gut Bacterial Processes to the Overall Biotransformation
- (2010) D. J. Sweeny et al. DRUG METABOLISM AND DISPOSITION
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases
- (2009) Debjani Ghosh et al. AUTOIMMUNITY
- Syk and pTyr'd: Signaling through the B cell antigen receptor
- (2009) Robert L. Geahlen BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
- (2009) Andrew X. Zhu et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
- (2009) Christopher G. Willett et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- Developmental toxicity associated with receptor tyrosine kinase Ret inhibition in reproductive toxicity testing
- (2008) George R. Clemens et al. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
- Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk
- (2008) A. Podolanczuk et al. BLOOD
- Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
- (2008) R Torrisi et al. BRITISH JOURNAL OF CANCER
- Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy
- (2008) Balazs Dome et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
- Endothelial and Hematopoietic Progenitor Cells (EPCs and HPCs): Hand in Hand Fate Determining Partners for Cancer Cells
- (2008) Süleyman Ergün et al. Stem Cell Reviews and Reports
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now